← Search & browse all drugs
NERVOUS SYSTEM › PSYCHOANALEPTICS › ANTIDEPRESSANTS › Non-selective monoamine reuptake inhibitors
iprindole
N06AA13
Forms & Strengths
- Oral tablets: 15 mg
- Oral tablets: 30 mg
Adult Dosing
- Initial: 30 to 45 mg daily in divided doses
- Maintenance: Up to 90 to 150 mg daily based on clinical response
- Maximum daily dose: 150 mg
Pediatric Dosing
- Safety and efficacy not established in pediatric patients (< 18 years)
Indications
- Treatment of major depressive disorder
Mechanism of Action
- Atypical tricyclic antidepressant
- Inhibits neuronal reuptake of norepinephrine and serotonin
- Displays minimal anticholinergic activity compared to traditional tricyclics
Contraindications
- Hypersensitivity to iprindole or other tricyclic antidepressants
- Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation
- Acute recovery phase following myocardial infarction
Adverse Reactions
- Drowsiness and sedation
- Dry mouth
- Constipation
- Orthostatic hypotension
- Blurred vision
- Weight gain
Drug Interactions
- Monoamine oxidase inhibitors (MAOIs): Risk of severe, potentially fatal serotonin syndrome or hypertensive crisis
- Central nervous system depressants (alcohol, barbiturates, benzodiazepines): Enhanced sedation and respiratory depression
- Sympathomimetic agents (epinephrine, norepinephrine): Potentiated cardiovascular effects
- Antihypertensive drugs: Increased risk of orthostatic hypotension
Curated Content: Needs Vetting Before Put to Clinical Use